| __timestamp | Axsome Therapeutics, Inc. | Celldex Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 20622000 |
| Thursday, January 1, 2015 | 2419289 | 33837000 |
| Friday, January 1, 2016 | 6343648 | 35979000 |
| Sunday, January 1, 2017 | 7206691 | 25003000 |
| Monday, January 1, 2018 | 9351522 | 19269000 |
| Tuesday, January 1, 2019 | 13598030 | 15426000 |
| Wednesday, January 1, 2020 | 28896749 | 14456000 |
| Friday, January 1, 2021 | 66646205 | 20488000 |
| Saturday, January 1, 2022 | 159253661 | 27195000 |
| Sunday, January 1, 2023 | 323123000 | 30914000 |
| Monday, January 1, 2024 | 411359000 |
Data in motion
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Axsome Therapeutics, Inc. and Celldex Therapeutics, Inc. over the past decade.
Axsome Therapeutics has seen a staggering increase in SG&A expenses, growing from a modest $1.4 million in 2014 to over $323 million in 2023. This represents a growth of over 23,000%, reflecting the company's aggressive expansion and investment in its operations.
In contrast, Celldex Therapeutics has maintained a more stable trajectory, with expenses peaking at $36 million in 2016 and stabilizing around $31 million by 2023. This steady approach may indicate a more conservative growth strategy.
The divergent paths of these companies highlight different strategic approaches in the biotech industry, with Axsome focusing on rapid expansion and Celldex opting for stability.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Celldex Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Celldex Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. or Verona Pharma plc: Who Manages SG&A Costs Better?
Axsome Therapeutics, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Axsome Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Axsome Therapeutics, Inc. and Novavax, Inc.
Who Optimizes SG&A Costs Better? Xenon Pharmaceuticals Inc. or Celldex Therapeutics, Inc.
Vericel Corporation and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
Arrowhead Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends